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Abstract
SUMO is a small post-translational modifier, that is attached to lysine residues in target proteins. It acts by altering protein-
protein interactions, protein localisation and protein activity. SUMO chains can also act as substrates for ubiquitination,
resulting in proteasome-mediated degradation of the target protein. SUMO is removed from target proteins by one of a
number of specific proteases. The processes of sumoylation and desumoylation have well documented roles in DNA
metabolism and in the maintenance of chromatin structure. To further analyse the role of this modification, we have
purified protein complexes containing the S. pombe SUMO protease, Ulp2. These complexes contain proteins required for
ribosome biogenesis, RNA stability and protein synthesis. Here we have focussed on two translation initiation factors that
we identified as co-purifying with Ulp2, eIF4G and eIF3h. We demonstrate that eIF4G, but not eIF3h, is sumoylated. This
modification is increased under conditions that produce cytoplasmic stress granules. Consistent with this we observe partial
co-localisation of eIF4G and SUMO in stressed cells. Using HeLa cells, we demonstrate that human eIF4GI is also sumoylated;
in vitro studies indicate that human eIF4GI is modified on K1368 and K1588, that are located in the C-terminal eIF4A- and
Mnk-binding sites respectively.
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Introduction
Sumoylation is a post-translational protein modification that is
required for numerous processes within cells, including transcrip-
tion, chromosome segregation, DNA damage responses, cell
signalling and meiosis (reviewed in [1–7]). At the molecular level
it functions by altering the surface of target molecules to affect
protein-protein interactions e.g. of PCNA (proliferating cell
nuclear antigen) and Srs2 (a DNA helicase) [8,9], by altering the
intracellular localisation of proteins e.g. of RanGAP [10], or by
changing the conformation of target proteins (e.g. in the case of
thymine DNA glycosylase [11]). SUMO chains attached to target
proteins can also be ubiquitinated and thus result in proteolysis of
the target.
SUMO is a small ubiquitin-like modifier that is attached to
lysine residues in target proteins. The yeasts Schizosaccharomyces
pombe and Saccharomyces cerevisiae both have a single gene for
SUMO: pmt3 and SMT3, respectively, while mammals have four,
SUMO-1, -2, -3 and -4 (although the role of SUMO-4 is not well
defined). SUMO-2 and -3 are 97% identical to each other and
about 50% identical to SUMO-1 (reviewed in [1]). SUMO is
produced as a precursor protein that needs to be cleaved into the
mature form in order to act as a substrate in the sumoylation
reaction. Processing of SUMO requires a specific SUMO-protease
[12–14], and involves the removal of a small number of amino
acids from the C-terminus of precursor SUMO to reveal a Gly-
Gly motif. Mature SUMO is then activated by the formation of a
thioester bond between the C-terminal glycine residue and a
cysteine residue in one subunit of the SUMO activating enzyme
(E1). From here SUMO is passed to the SUMO conjugating
enzyme (E2), where it again forms a thioester bond with another
cysteine residue. SUMO can then be attached to one or more
lysine residues in the target protein. In some cases, one of a small
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number of SUMO ligases (E3) is required for conjugation. In
many cases the lysine is contained within the consensus motif
yKxE, where y is a hydrophobic amino acid, and x is any amino
acid. SUMO can be added to target proteins as a monomer or as
poly-SUMO in the form of chains. The removal of SUMO from
target proteins or dismantling of SUMO chains occurs via the
action of SUMO-specific proteases [14,15].
In S. cerevisiae there are two SUMO proteases, Ulp1 and Ulp2,
both of which can deconjugate SUMO from target proteins, but
which have different target specificities [12]. Only Ulp1 is capable
of processing precursor SUMO to the mature form [12,15]. Ulp1
and Ulp2 are differently localised within the cell: Ulp1 is located at
nuclear pores, while Ulp2 is located mainly within the nucleus
[15]. Mammalian cells have six SUMO-specific proteases
(SENPs). These are also differentially localised within cells and
have different abilities to cleave precursor SUMO and to
deconjugate SUMO from targets e.g. [16,17]. The S. pombe Ulp1
protease has been characterised and shown to process SUMO to
the mature form, and like S. cerevisiae Ulp1, to be located at the
nuclear periphery [13]. However, little is known about Ulp2 in this
organism.
Translation initiation factors, which play key roles in cell
survival and oncogenesis [18–22], can be modified by sumoylation
[6,7,23–31]. Protein synthesis is carried out in three stages
(initiation, elongation and termination), with the initiation stage
of translation generally accepted as a major site of regulation of
gene expression in mammalian cells [18–22]. This step in protein
synthesis is regulated by a family of proteins, the initiation factors
[18,21,22] which interact with each other and the mRNA. These
proteins modulate the binding of mRNA to the ribosome, a
process facilitated by the assembly of the cap binding protein
(eIF4E), a helicase (eIF4A) and a scaffold protein (eIF4G), to form
the eIF4F complex (eIF4E/eIF4A/eIF4G). The eIF4G scaffold
protein possesses domains that interact with eIF4E, eIF4A, eIF3
and the poly(A) binding protein (PABP) [18,20–22]. The activity of
the eIF4F complex is regulated by a family of proteins, the eIF4E
binding proteins (4E-BPs). Using a conserved motif, 4E-BPs
compete with eIF4G for a common surface on eIF4E and inhibit
eIF4F assembly. In mammalian cells, activation of the mechanistic
target of rapamycin (mTORC1) leads to the multi-site phosphor-
ylation of 4E-BP1 [18,22,32] preventing 4E-BP1 from binding to
eIF4E and thereby allowing formation of the eIF4F initiation
complex and ribosomal recruitment of mRNA [18,21,22]. More
recently, phosphorylated human eIF4E has been shown to be
modified by sumoylation on five lysine residues [33]. Consistent
with a role in modulating protein-protein interactions [34],
sumoylation did not interfere with mRNA recognition but
enhanced eIF4F complex level assembly on the mRNA cap,
promoting the expression of ornithine decarboxylase, c-myc and
Bcl-2, thereby driving the anti-apoptotic and oncogenic activity of
eIF4E [33].
Since the majority of SUMO in cells is present in the nucleus,
much of the work undertaken to understand the role of
sumoylation has focussed on its role in regulating events associated
with DNA metabolism, such as the maintenance of chromatin
structure, recombination and DNA damage responses [3,5,8,9].
More recently it has been demonstrated that sumoylation is
required in the nucleolus to regulate ribosome biogenesis e.g. [35].
In order to obtain a fuller understanding of the role of sumoylation
we have begun to investigate the protein-protein interactions and
localisation of the mostly uncharacterised S. pombe SUMO
protease, Ulp2. Our results from gel filtration and immunofluo-
rescence studies indicate that Ulp2 is present in at least two high
Mr complexes, which are distinct from the nuclear pore complex
that contains Ulp1. We demonstrate that it co-purifies with a
number of proteins, many of which are involved in RNA
metabolism or protein synthesis. We have investigated whether
two of these proteins, eIF4G and eIF3h, are sumoylated, with the
result that we observe SUMO modification of eIF4G but not
eIF3h. Exposure of cells to conditions that lead to the formation of
stress granules, results in increased sumoylation of eIF4G, and
partial co-localisation of eIF4G and SUMO in the cytoplasm.
Finally, we demonstrate that human eIF4G is sumoylated in HeLa
cells, by both SUMO-1 and SUMO-2.
Materials and Methods
Strains and plasmids
The strains used in this work are described in Table 1. The
strains containing myc-, HA or TAP-tagged ulp1, ulp2, pli1, eIF4G
and eIF3h were created using the method of Bahler et al [36].
pREP41-His-SUMO was constructed by cloning the pmt3 ORF
into pREP41-His (created in this study). The S. pombe and human
eIF4G and eIF4GI constructs, Sp C-term, N-FAG, M-FAG and
C-FAG contain different fragments of the eIF4G/eIF4GI Orfs
cloned into pET15b [37]. HeLa cell lines stably transfected with
His-SUMO-1 and His-SUMO-2 were gifts from Prof R Hay
(University of Dundee) [38,39].
Ulp2 expression and assay
The ulp2 ORF was amplified from cDNA, by PCR and cloned
into pFastBacHTa (GibcoBRL). Recombinant baculoviruses were
generated according to GibcoBRL instructions. 50 ml infected
cells were lysed in 50 mM Tris HCl pH 8, 5 mM b-mercapto-
ethanol, 1% nonidet, 1 mM PMSF. Ulp2 protein was purified
using Talon resin. Ulp2 activity assays were conducted as
described for Ulp1 [13].
Protein purification methods
His-tagged SUMO was recovered from S. pombe and human
whole cell extracts under denaturing conditions with Ni2+ agarose
beads. Cell extracts were prepared as follows: 108 cells (S. pombe) or
6–86106 cells (Hela) were washed in ice cold water before being
lysed by vortexing in 1.85 M NaOH, 7.5% v/v b-mercaptoeth-
anol. The lysate was incubated on ice for 20 min after which TCA
was added to a final concentration of 25%. Following a further
20 min incubation on ice, precipitated proteins were collected by
centrifugation and resuspended and solubilised in 1 ml buffer A
(6 M guanidinium HCl, 0.1 M NaH2PO4, 10 mM Tris-HCl,
pH 8). Insoluble material was removed by centrifugation. The cell
extract was then incubated with Ni2+ agarose (Novagen) in Buffer
A in the presence of 0.05% Tween-20, 150 mM imidazole.
Purification on Ni2+ agarose was carried out according to the
manufacturer’s instructions. Samples were analysed by SDS-
PAGE and Western blotting. His-tagged S. pombe and human
eIF4GI fragments for in vitro sumoylation assays were purified from
E. coli using Ni2+ agarose according to the manufacturer’s
instructions.
For gel filtration, 200 ml logarithmically growing cells were
harvested, washed and then broken in 1 ml ice cold lysis buffer
(45 mM HEPES pH 7.8, 300 mM KCl, 5 mM MgCl2, 5 mM
EDTA, 5 mM EGTA, 12 mM NaF, 10% glycerol, 80 mM b-
glycerophosphate, 0.1 mM sodium orthovanadate, 1 mM PMSF,
1 mM DTT, supplemented with Roche complete protease
inhibitor). The extract was clarified by two rounds of centrifuga-
tion at 20,000 rpm for 10 min. 1.5 mg protein was loaded onto
either a Superdex 200 or Superose 6 column pre-equilibrated in
S. pombe Ulp2
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lysis buffer. 0.5 ml fractions were collected and 15 ml of each was
analysed by SDS PAGE.
For TAP-purification, 60 l ulp2-TAP cells were grown to mid-log
phase, harvested and frozen at 280uC until required. Ulp2-TAP
was purified using a modification of the method described by
Seraphin et al. [40]. Specifically, the cells were broken in a 6850
freezer mill in 20 mM Tris-HCl, pH 7.5, 10 mM NaCl, 1 mM
DTT, 0.5 mM EDTA, 2 mM MgCl2, 0.1 mM NaF, 0.1%
Nonidet NP40, 1 mM PMSF, 5 mM sodium orthovanadate,
80 mM b-glycerophosphate, 10 mM N-ethylmaleimide, supple-
mented with Roche complete protease inhibitor. All subsequent
procedures were carried out at 4uC. The cell extract was
centrifuged twice for 1 h at 10,000 rpm. Samples were pre-
cleared by incubation with 200 ml Dynabeads for 30 min to
remove proteins that bound non-specifically to the beads. The
extracts were incubated with 300 ml IgG-coated Dynabeads for
2 h. The beads were collected and washed extensively before
being resuspended in TEV buffer (50 mM Tris-HCl pH 8.0,
0.5 mM EDTA, 1 mM DTT) with 250 units AcTEV protease
(Invitrogen) for 3 h. The IgG-coated Dynabeads were removed
from the preparation and Ulp2-TAP containing complexes were
snap frozen in liquid nitrogen.
In vitro sumoylation assay
Recombinant His-tagged S. pombe eIF4G and human eIF4GI
fragments were purified from E. coli and tested for sumoylation in
an in vitro sumoylation assay as described elsewhere [41]. SUMO-
TRGG (Pmt3-L109R,GG: the mature form of S. pombe SUMO
containing a trypsin cleavage site immediately upstream of the
diglycine motif) was used in the assay to facilitate the identification
of the sumoylation sites by mass spectrometry.
Immunological methods
Western analysis was carried out as described previously [13].
Production of anti-SUMO and anti-eIF4GI (against the KRERK
epitope) antisera has been described elsewhere [41,42], anti-myc
antibodies for immunofluorescence were purified from cell
supernatant (cell line CRL1729, from ATCC) using protein G-
sepharose or were from Santa Cruz (sc-40), anti-HA antisera were
from Santa Cruz (sc-7392) and monoclonal anti-tubulin antibodies
were from Sigma (T5168). Immunofluorescence was undertaken
as described in Moreno et al. [43]. Cells were observed using an
Applied Precision Deltavision Spectris microscope using deconvo-
lution software.
Mass spectrometry
Complexes purified by purification of TAP-Ulp2 were analysed
by SDS PAGE. Protein bands were visualised by staining with
colloidal Coommassie, excised and subjected to trypsin in-gel
digestion essentially as described by Schevchenko et al. [44]. The
supernatant from the digested samples was removed and acidified
to 0.1% TFA, dried down, and reconstituted in 0.1% TFA prior to
LC MS/MS analysis. Each sample was loaded and desalted at a
flow rate of 5 ml/min on a C18 trap column (200 mm ID x 1 cm,
5 mm PepMap 100, Dionex) in buffer A (acetonitrile (2% v/v):
water (97.9% v/v): formic acid (0.1% v/v)). The tryptic peptides
were fractionated on a C18 reverse phase column (75 mm ID x
25 cm, 3 mm PepMap 100, Dionex) using an Ultimate U3000
nano-LC system (Dionex) and a 2 hr linear gradient from 95%
buffer A to 50% buffer B (acetonitrile (95% v/v): water (4.9% v/v):
formic acid (0.1% v/v) at a flow rate of 300 nl/min. Eluted
peptides were directly analysed by tandem mass spectrometry
using a LTQ Orbitrap XL hybrid FTMS (ThermoScientific)
operated in parallel acquisition IDA mode with nominal resolution
of 60,000 (FWHM) at m/z 400 for MS1 and the top six most
abundant multiply charged ions being selected for CID fragmen-
tation in the linear ion trap followed by dynamic exclusion for
90 secs.
Derived MS/MS data were searched against the S. pombe subset
of the UniProt Knowledgebase release 15.13 database using
Sequest version SRF v. 5 as implemented in Bioworks v 3.3.1
(Thermo Fisher Scientific), assuming carboxyamidomethylation
(Cys), deamidation (Asn and Gln) and oxidation (Met) as variable
modifications and using a peptide tolerance of 10 ppm and a
fragment ion tolerance of 0.8 Da. One missed cleavage was
allowed and filtering criteria used for positive protein identifica-
tions were Xcorr values greater than 1.9 for +1 spectra, 2.2 for +2
spectra and 3.75 for +3 spectra and a delta correlation (DCn) cut-
off of 0.1.
Table 1. List of strains.
Strain Genotype Reference
Sp.011 ade6-704, leu1-32, ura4-D18, h2 [72]
Sp.611 ulp1-myc:kan, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.614 ulp2-myc:kan, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.658 ulp1::ura4, ade6-704, leu1-32, ura4-D18, h2 [13]
Sp.723 pli1-myc:kan, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.874 pmt3-GG:ura4, ade6-704, leu1-32, ura4-D18, h2 This study
sp.851 ulp1::ura4, pmt3-GG:ura4, ade6-704, leu1-32, ura4-D18, h2 This study
sp.855 ulp2::ura4, pmt3-GG:ura4, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.1470 ulp2-TAP, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.2047 eIF3h-HA:Nat, ade6-704, leu1-32, ura4-D18, h+ This study
Sp.2048 ulp2-myc:kan, eIF3h-HA:Nat, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.2068 ulp2-myc:kan, eIF4G-HA:Nat, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.2085 ulp2::kan, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.2088 eIF4G-HA:Nat, ade6-704, leu1-32, ura4-D18, h+ This study
doi:10.1371/journal.pone.0094182.t001
S. pombe Ulp2
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For the identification of sumoylation sites, reduction and
alkylation were instead performed using TCEP and MMTS
respectively as previously described [45] and bioinformatics
analysis following conversion of LTQ-Orbitrap (.raw) raw data
files to Mascot generic format (MGF) via Mascot Distiller (Matrix
Science) performed essentially as described by Chicooree et al.
[46] using the MASCOT search engine with the UniProt
Knowledgebase release 15.13 database with the S. pombe subset
as selected taxonomy. Precursor ion tolerances were again set at
10 ppm and MS/MS peptide ion tolerance to 0.8 Da, and the
same variable modifications assumed. However, two missed
trypsin cleavages were allowed.
Following trypsin digestion, cleavage of the SUMO moiety was
expected to leave a Gly-Gly isotag on modified residues. The GG
isotag (on lys) was accordingly also searched as a variable
modification. Following MASCOT searches, putative sites of
SUMOylation were noted and the relevant raw MS/MS spectra
subsequently examined manually to confirm presence of the
modification (the GG isotag).
Results
Biochemical characterisation of S. pombe Ulp2
A comparison of the S. pombe Ulp2 sequence was made with
those of the two S. cerevisiae SUMO proteases, Ulp1 and Ulp2 [47].
Since S. pombe Ulp2 more closely resembles S. cerevisiae Ulp2
(required solely for deconjugating SUMO from high Mr SUMO-
containing species) than it does Ulp1 (which is required for both
processing and deconjugating), it is likely that the main activity of
S. pombe Ulp2 is in deconjugating SUMO from sumoylated targets
rather than in processing SUMO to the mature form. Before
proceeding to analyse the localisation or protein-protein interac-
tions of Ulp2, we first confirmed its proposed biochemical activity.
His-tagged Ulp2 was purified from insect cells as described in
Materials and Methods. Using assays we described previously [13],
we demonstrate that Ulp2 is significantly less able than Ulp1 to
process SUMO to the mature form (Figure 1A, lane 2 (Ulp1) and
lane 3 (Ulp2)), but is capable of deconjugating SUMO from high
Mr species in an N-ethylmaleimide- (NEM)-dependent manner
(Figure 1B). These results confirm that like S. cerevisiae Ulp2, S.
pombe Ulp2 is a cysteine protease whose main function is in
deconjugating SUMO from target proteins.
Deletion of the ulp2 gene results in a severe growth
defect and sensitivity to a range of stresses
Deletion of pmt3 (which encodes SUMO), hus5 (the gene
encoding the SUMO-conjugating enzyme, E2), rad31 (which
encodes one sub-unit of the SUMO activating enzyme, E1) or ulp1
(another SUMO-specific protease gene) results in severe growth
and morphological abnormalities [13,48–50]. We therefore wished
to determine whether disrupting the ulp2 gene has any effect on
cell growth or viability. Disruption of the gene is not lethal.
However, ulp2-d cells form very small colonies and show distinct
morphological abnormalities resembling hus5 and rad31 mutants
(data not shown). Comparison of SUMO-containing species in
ulp1-d and ulp2-d cells (Figure 1C, lanes 3 and 4) supports the
notion that the main function of Ulp2 is in the removal or
dismantling of high Mr SUMO-containing species, rather than in
processing precursor SUMO. Provision of the mature form of
SUMO (Pmt3-GG) in ulp1-d cells (lane 5) results in the
incorporation of SUMO into high Mr species (unlike the situation
in ulp1-d cells, lane 3), while in ulp2-d cells (lane 6), the level of high
Mr species is slightly increased.
To begin to identify cellular processes involving Ulp2, we tested
whether ulp2-d cells are sensitive to the DNA synthesis inhibitor,
hydroxyurea (HU) and other stresses (Figure 1D), and compared
these responses to those of ulp1-d,pmt3-GG cells (where the mature
form of SUMO is provided, so that cells are only defective in the
deconjugating activity of Ulp1). Since ulp2-d and ulp1-d,pmt3-GG
cultures contain a high proportion of dead cells, it was necessary to
plate more cells for these strains compared to wild type
(approximately 10 fold). These data indicate that ulp2-d cells are
temperature sensitive, unlike the ulp1-d,pmt3-GG strain, but similar
to the S. cerevisiae ulp2D strain [51], and sensitive to the DNA
synthesis inhibitor, hydroxyurea (HU, 2 mM). They are also
sensitive to the protein synthesis inhibitor, cycloheximide (CHX,
10 and 20 mg/ml) and KCl (1 M) indicating that Ulp2 likely has
roles in numerous cellular processes.
Ulp2 is present in high molecular weight complexes
Throughout most of the cell cycle, Ulp1 is associated with the
nuclear envelope [13], and specifically with the nuclear pore
complex [52,53]. To determine whether Ulp2 is also part of a high
Mr complex we undertook gel filtration analysis. Figure 2A
indicates that, as expected, Ulp1 elutes in the void volume,
consistent with it being present in a high Mr complex. Ulp2 also
elutes in the void volume like Ulp1, but additionally, it is present in
fractions corresponding to an approximate Mr of 670 kDa. This
suggests that Ulp2 is likely to be present in at least two different
complexes. In contrast to the results obtained for Ulp1 and Ulp2,
Pli1, an E3 SUMO ligase [54], does not elute in these high Mr
fractions, implying that it likely exists in cells as a monomer or
possibly a dimer.
Ulp2 is located in both the nucleus and cytoplasm, but is
predominantly nuclear
Since a proportion of Ulp2 co-elutes with Ulp1 in the void
volume, we wished to determine whether some or all of the Ulp2
co-localises with Ulp1 in cells, i.e. is at the nuclear periphery. We
therefore analysed the localisation of Ulp2. Figure 3 indicates that
Ulp2 is present in foci that are predominantly nuclear, with a small
proportion in the cytoplasm. Little if any Ulp2 is located at the
nuclear periphery. Thus the location of Ulp2 is distinct from that
of Ulp1 [13], indicating that it is unlikely to be part of nuclear pore
complexes. In many cases, Ulp2 co-localises with SUMO. Ulp1
undergoes distinct changes in localisation during the cell cycle, its
localisation changing from the nuclear periphery where it is for
most of the cell cycle, to the region between the separating DNA
masses during mitosis [13]. In contrast, the location of Ulp2
appears to be relatively unchanged in cells at different cell cycle
stages. For example, during mitosis (Figure 3, TRITC panel, cells
labelled 4), a time when Ulp1 relocalises, the distribution of
intranuclear Ulp2 foci is very similar to that observed at other
times in the cell cycle (cells labelled 1–3) and is unchanged.
Ulp2 co-purifies with proteins associated with RNA
metabolism and protein synthesis
To begin to identify the nature of the complexes observed in
Figure 2, we C-terminally-tagged Ulp2 with TAP in the genome
(ulp2-TAP) and isolated the tagged protein and associated proteins
as described in Materials and Methods. Protein complexes were
analysed by SDS PAGE (Figure 4) and fractions excised from the
gel for mass spectrometric analysis. As shown in Table S1 and
Table 2, the majority of the proteins identified are associated with
RNA metabolism, such as RNA processing, ribosome biogenesis
or initiation of translation. To ensure that these proteins co-
S. pombe Ulp2
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purified specifically with Ulp2, a parallel purification was
undertaken using Rad9-TAP, and from cells expressing the TAP
tag alone (Figure S1). Rad9 is a member of the 9-1-1 complex
required for the DNA integrity checkpoint [55], and would not be
expected to interact with a the same proteins as those that interact
with Ulp2. Very little protein co-purified with the TAP-tag alone,
while purification of Rad9-TAP yielded a quite different set of
bands. Most of the proteins co-purifying with Rad9 were
associated with DNA metabolism as expected (data not shown)
and only one protein, glyceraldehyde 3-phosphate dehydrogenase,
was common to the Ulp2-TAP and Rad9-TAP preparations.
A number of proteins required for ribosome biogenesis,
including some of those we identified by mass spectrometry, have
recently been demonstrated to be sumoylated (Table 2) [6,7,23–
27,56–58]. However, little is known about the effect of sumoyla-
tion on the function of translation factors. We therefore selected
two translation initiation factors, eIF4G and eIF3h for further
study. The analysis of some of the other factors will be described
elsewhere. eIF4G has been well characterised in S. cerevisiae and
mammalian cells [18,22] and to some extent in S. pombe [59].
eIF4G acts as a scaffold protein as part of the eIF4F complex to
recruit mRNA to the ribosome for translation [21], while eIF3h is
a non-core subunit of the eIF3 complex linking eIF4F/mRNA to
the ribosome in mammalian cells [60]. Gel filtration analysis of
whole cell extracts from cells containing Ulp2-myc and either
eIF4G-HA or eIF3h-HA indicates that the majority of eIF4G co-
elutes with Ulp2 (Figure 2B). In contrast, eIF3h elutes in multiple
Figure 1. Analysis of Ulp2 function. A. Assay for SUMO-processing activity. Lanes 1–4 contain full length SUMO, lane 5 SUMO-GG. Lanes 1,5,
unincubated controls, lanes 2–4 were incubated at 20uC for 2 h following addition of 0.72 mg Ulp1 (lane 2), 2.32 mg Ulp2 (lane 3) or 2 ml buffer (lane
4). Proteins were analysed by SDS PAGE followed by staining with Coommassie Brilliant Blue. B. Assay for de-conjugating activity. S. pombe cell
extracts were prepared using standard native extraction procedures. Extracts were incubated at 20uC for 2 h (lanes 1–6), lane 1 5 ml of fraction from
extract from E. coli cells transformed with empty vector, equivalent in volume to the Ulp2-containing fraction from ulp2-transformed cells, lane 2
0.6 mg Ulp2, lane 3 1.2 mg Ulp2, lane 4 2.4 mg (5 ml) Ulp2, lane 5 4.8 mg Ulp2, lane 6 1.2 mg Ulp2 pre-incubated with 5 mM NEM, lane 7 total cell extract
without incubation at 20uC. Assays were analysed by Western blotting with anti-SUMO antisera. C. Western analysis of total cell extracts using anti-
SUMO antisera. Both the separating and stacking gels (6% polyacrylamide in the stacking gel) were blotted. D. Ten microlitre of 10 fold serial dilutions
of cells were plated onto YEP agar plates with or without additives as indicated. 10x amount of cells of ulp2-d and ulp1-d,pmt3-GG were used
compared to wild type.
doi:10.1371/journal.pone.0094182.g001
S. pombe Ulp2
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Figure 2. Ulp2 is present in high Mr complexes. Analysis of complexes by gel filtration. A. Total cell extracts from ulp1-myc, ulp2-myc or pli1-myc
strains were analysed on a Sephadex 200 column, and fractions were western blotted with anti-myc antibodies. B. Total cell extracts from ulp2-
myc,eIF4G-HA and ulp2-myc,eIF3h-HA strains were analysed on a Superose 6 column, fractions were western blotted with anti-myc and anti-HA
antibodies.
doi:10.1371/journal.pone.0094182.g002
Figure 3. Ulp2 is localised predominantly within the nucleus. A. Cells containing myc-tagged ulp2 as the sole copy of the ulp2 gene were
incubated with anti-myc antisera (mouse monoclonal) and anti-SUMO antisera (rabbit polyclonal) followed by TRITC-conjugated anti-mouse IgG
antisera, FITC-conjugated anti-rabbit IgG antisera and DAPI. Merge = overlay of TRITC (red), FITC (green) and DAPI (blue) staining. 1: early G2 cells,
2,3: late G2 cells, 4: mitotic cells, 5: S phase cells. Bar = 5 mm.
doi:10.1371/journal.pone.0094182.g003
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fractions, suggesting it is present in several different sized
complexes.
eIF4G, but not eIF3h, is sumoylated in S. pombe
One possibility to explain the interaction of eIF4G and eIF3h
with the SUMO protease Ulp2 is that they are themselves
modified by SUMO. In order to determine whether this is the
case, cells containing genomic copies of HA-tagged eIF4G or
eIF3h were co-transformed with pREP41-His-SUMO. His-tagged
SUMO was purified on Ni2+ agarose. Denaturing conditions (with
6 M guanidinium HCl in the binding buffer, followed by 6 M
urea, 300 mM imidazole washes) were used to ensure that
sumoylation of the individual proteins was being observed, rather
than that of other components of the eIF4F or eIF3 complexes).
Figure 5A, shows that eIF4G is specifically recovered in the
presence of His-tagged SUMO (lane 1), but not in the absence of
His-tagged SUMO (lane 2), indicating that it is sumoylated in S.
pombe. In contrast, eIF3h is not recovered in either the absence or
presence of His-tagged SUMO (Figure 5B), indicating that this
translation factor is not sumoylated in fission yeast. Its co-
purification with Ulp2 may thus be through the interaction of
Ulp2 with other member(s) of the eIF3 complex.
Conditions that induce stress granules affect the
localisation and sumoylation of eIF4G
Since one of the functions of sumoylation is to affect protein
localisation, we next investigated whether eIF4G and SUMO co-
localise. Figure 6 shows that in untreated cells, as has been shown
previously [61], the majority of eIF4G is cytoplasmic as expected
for a translation initiation factor. As has been observed in S.
cerevisiae and human cells [62,63], a small amount of eIF4G is also
present in the nucleus, where it is proposed to couple RNA
processing events in the nucleus with translation in the cytoplasm.
In contrast to the situation with eIF4G, the majority of the SUMO
protein is present in the nucleus (Figures 3 and 6). We observe that
a significant proportion of the nuclear eIF4G co-localises with
SUMO, suggesting sumoylation of eIF4G may have a role in
regulating RNA processing or localisation.
Protein synthesis can be inhibited by a variety of factors. For
example, cycloheximide (CHX) interacts with ribosomes and
inhibits the elongation step, while exposure of S. pombe cells to 1 M
KCl inhibits protein synthesis by the sequestration of translation
initiation factors and mRNA into cytoplasmic stress granules [64].
Following treatment with CHX, eIF4G staining is slightly more
punctate than in untreated cells, while the pattern of SUMO
staining is unchanged. In these cells, there is a low level of
colocalisation of eIF4G and SUMO in the nucleus. Interestingly,
exposure of cells to CHX results in distorted nuclei. The reason for
this is not known, but it could be due to disruption of RNA
processing and/or localisation by CHX.
In S. pombe and mammalian cells eIF4G and eIF4GI respec-
tively, are among the translation factors present in stress granules
[61,65,66]. To investigate stress granule formation in S. pombe, we
exposed cells to 1 M KCl. In these cells, eIF4G is present in fewer,
but quite bright, punctate cytoplasmic foci (Figure 6). This pattern
of staining is similar to what has been observed for stress granules
in S. pombe, and in particular, what has previously been observed
for eIF4G in this organism [61,64]. In these cells, there was
occasional co-localisation of the two proteins in the cytoplasm and
this appeared to reflect the appearance of eIF4G and SUMO in
the same granule.
Figure 4. Purification of Ulp2-TAP. SDS-PAGE of Ulp2-Tap and
associated proteins. TEV = TEV protease, used to cleave Ulp2 from TAP
tag. Numbers refer to gel slices analysed by mass spectrometry.
doi:10.1371/journal.pone.0094182.g004
Table 2. Summary of proteins identified by mass spectrometry that co-purified with TAP-Ulp2.
Function Protein
Translation eIF2a, eIF2b, eIF3a, eIF3b, eIF3c, eIF3c, eIF3h, eIF4G, EF1a EF2B, eEF3B, EF2, Pabp
RNA synthesis Rpa1, Rpa2,
RNA processing Rrp5, SPAC694.02, Exo2, Dhp1, Upf1, SPBC19G7.10C, Nop2, Dbp2, Prp19, Sla1,
Ribosome biogenesis aconitate hydrolase/mitochondrial ribosomal protein subunit L49, SPAC22G7.05, SPAC1142.04(Noc2 predicted), Hsc1/Sks2, Rpl301,
Rpl302, Rml2
DNA metabolism Tcg1, Rfc5,
Other Pfk1, SPBC16h5.12C, glutamate 5-kinase (predicted), Gpd1, Gpd3
Data from [6,7,23–26,56–58].
doi:10.1371/journal.pone.0094182.t002
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Another protein known to be present in stress granules is polyA-
binding protein (PABP) [61]. We therefore compared the
localisation of eIF4G and PABP in cells exposed to 1 M KCl.
We observe PABP in large cytoplasmic granules, which are
different to those we observe in cells only containing HA-tagged
eIF4G-HA (Figure S2A and Figure 6). Curiously, in some of the
cells that contain both eIF4G-HA and PABP-RFP, eIF4G is now
also present in large granules where it co-localises with PABP.
Further analysis of PABP-RFP containing cells indicated that a
proportion of the SUMO is mislocalised to the cytoplasm (Figure
S2B). This suggests that C-terminal RFP-tagging of PABP may
affect its function and/or localisation.
Following exposure to 1 M KCl, we noticed that there was less
staining of both eIF4G and SUMO compared to that in untreated
cells. Western analysis of eIF4G and SUMO levels indicates that
in response to 1 M KCl the levels of both proteins are significantly
reduced (Figure 5C). The reason for this is unknown, but may be
due to the fact that a proportion of the eIF4G and SUMO is
insoluble and not recovered in the extract. Alternatively, and in
our view the more likely explanation, we propose that in response
to this stress, there is increased proteolysis of both proteins.
We next investigated whether sumoylation of eIF4G is affected
by exposure of cells to either CHX (100 mg/ml) or KCl (1 M).
Figure 7A indicates that there is an increase in sumoylation in
response to KCl, with levels of sumoylation unaffected by exposure
to CHX, when compared to levels in untreated cells (with relative
levels being 1:1:1.5; wt, CHX-treated, KCl-treated, respectively).
These data suggest that sumoylation of eIF4G may be associated
with stress granule formation and/or proteolysis of the translation
initiation factor.
Human eIF4GI is sumoylated
In order to analyse the role of sumoylation of S. pombe eIF4G we
investigated the possibility of testing the protein for ability to be
sumoylated in our in vitro sumoylation assay, as this could help us
identify the sumoylated lysine residue(s). However, two factors
make this identification difficult. Firstly, in order to purify protein
for an in vitro sumoylation assay, we would need to clone the full
length S. pombe eIF4G cDNA. We have previously observed that
Figure 5. eIF4G, but not eIF3h, is sumoylated. His-tagged SUMO was expressed in cells containing genomically tagged (HA) copies of eIF4G (A)
and eIF3h (B). WCE = whole cell extract, PD = Ni2+-agarose pull down. Blots were probed with anti-HA or anti-SUMO antisera. C. Western blot of
whole cell extracts from cells containing genomically tagged eIF4G-HA. UT = untreated, C, K = incubated for 30 min with 100 mg/ml CHX (C) or 1 M
KCl (K).
doi:10.1371/journal.pone.0094182.g005
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plasmids containing the N-terminus of the S. pombe eIF4G coding
sequence cannot be tolerated in E. coli [59], so that full length
eIF4G cannot be expressed in E. coli. The reason for this is
unknown, but may be due to the presence of a highly repeated
sequence within the eIF4G coding sequence. Secondly, this highly
repeated sequence (present in the coding sequence in the S. pombe,
but not in the S. cerevisiae or human proteins) contains 16 repeats of
a perfect sumoylation site consensus motif (AKRE), which would
likely make identification of the site(s) difficult, even if we were able
to express the full length protein. We therefore expressed a C-
terminal fragment (comprising aa 970–1403), which contains
eIF4E, eIF4A and eIF3 binding sites (Figure 7B) and tested this in
our in vitro sumoylation assay. We did not observe any sumoylation
of this fragment, implying that sumoylation likely occurs in the N-
terminus of the protein.
To further analyse the role of sumoylation we set out to
determine whether human eIF4GI is sumoylated and if so, to
identify the sumoylation site(s) in this protein. We used HeLa cell
lines stably transfected with either His-SUMO-1 or His-SUMO-2
[38,39]. His-tagged SUMO was recovered from cell extracts
prepared under denaturing conditions. Figure 7C indicates that
eIF4GI is not recovered from extracts of cells that do not contain
His-tagged SUMO (lane1), but is isolated from extracts of cells
containing His-SUMO-1 (lane 2) and to a lesser extent from cells
expressing His-SUMO-2 (lane 3). This confirms that, like S. pombe
eIF4G, human eIF4GI is sumoylated.
We next sought to identify the sumoylation sites on human
eIF4GI. In order to facilitate our analysis, we used three different
human eIF4G fragments, N-FAG, M-FAG and C-FAG (Figure 7B,
[37]). These protein fragments were purified from E. coli and tested
in our in vitro sumoylation assay (data not shown). Slow migrating
forms of eIF4G were excised from gels and analysed by mass
spectrometry. Two sumoylation sites were identified: K1368 and
K1588 (Figure 7D). These map to two domains of eIF4GI which
interact with eIF4A and the protein kinase, Mnk1, respectively
[18,21,22]. These results suggest that sumoylation may affect the
interaction of eIF4GI with these two proteins.
Discussion
In order to analyse the role of S. pombe Ulp2, we purified Ulp2-
TAP-containing complexes. We identified proteins involved in
RNA synthesis or processing, ribosome biogenesis and translation.
This is consistent with recent reports that a number of proteins
required for ribosome biogenesis and RNA processing are
sumoylated [6,67,68]. While this manuscript was in preparation,
Figure 6. Effect of cycloheximide and KCl on localisation of eIF4G and SUMO. Cells containing eIF4G-HA, untreated (UT) or exposed to CHX
(100 mg/ml) or KCl (1 M) as indicated, were incubated with anti-SUMO antisera (green) and anti-HA antisera (red). Bar = 5 mm. Bottom panel, regions
indicated by boxes in panel above. Arrows indicate sites of colocalisation of SUMO and eIF4G.
doi:10.1371/journal.pone.0094182.g006
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a global analysis of the SUMO system interactome in S. cerevisiae
identified a range of proteins including a number required for
ribosome biogenesis and rRNA processing that interact with Ulp2
[69]. Additionally, the nucleolar SUMO-specific protease, SENP3,
has been demonstrated to reverse the SUMO modification of
nucleophosmin to be required for rRNA processing [70].
Although a number of translation factors, required for both the
initiation and elongation steps of protein synthesis, have been
identified in global screens as being sumoylated e.g. [23–28,30,31],
little is known about the role of sumoylation of these proteins. This
is in contrast to the situation with the role of sumoylation in
ribosome biogenesis. We therefore focussed our attention on two
S. pombe translation initiation factors in our list of Ulp2-interactors:
Figure 7. Human eIF4G is sumoylated. A. S. pombe cells containing His-tagged SUMO and HA-tagged eIF4G as indicated were treated with CHX
(100 mg/ml) or KCl (1 M), and His-tagged SUMO pulled down, and analysed as in Figure 5. B. Comparison of human and eIF4G proteins, indicating
protein binding domains: PABP= polyA binding protein, 4E = eIF4E, 4A = eIF4A, 3 = eIF3, Mnk = MAP kinase-interacting kinase 1. C. Whole cell
extracts (WCE) and Ni2+ pull-down (PD) from extracts of HeLa cells stably transfected with His-tagged SUMO-1 (S1) or SUMO-2 (S2) or nothing (-).
Western blots probed with anti-eIF4GI (KRERK epitope) antisera. D. Representative eIF4G ion mass spectra (MS/MS spectra) showing identification of
the in vitro sites of sumoylation.
doi:10.1371/journal.pone.0094182.g007
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eIF4G and eIF3h. Both proteins are known to be present in high
Mr complexes, with eIF4G being part of the eIF4F complex while
eIF3h is part of the eIF3 complex [22]. We demonstrate here that
eIF4G, but not eIF3h is sumoylated in vivo. These results are
supported by the genome-wide analyses of sumoylated proteins
that have been undertaken, that indicate that eIF4G is sumoylated
[24,28] but which have not to date identified eIF3h as a
sumoylation target.
As the most prominent role of translation initiation factors is in
cytoplasmic protein synthesis, we began by investigating whether
Ulp2 is associated with polysomes. However, we observed that
while Ulp2 migrated at the same position in sucrose gradients as
polysomes, it was still present in these fractions under conditions
(2.5 mM EDTA) where polysomes were disrupted, indicating that
the majority of Ulp2 is not associated with actively translating
polysomes (data not shown). This result confirms our gel filtration
analysis and localisation studies, and indicates that Ulp2 is present
in very high molecular weight complexes, but discounts the
possibility that Ulp2 is associated with actively translating
polysomes.
The role of sumoylation of translation factors has not been well
studied, apart from that of eIF4E [29,33]. eIF4E is an mRNA cap-
binding protein, and one of the proteins that interacts with eIF4G
to form the eIF4F complex [22]. eIF4E is regulated by
phosphorylation and by interaction with eIF4E-binding proteins
(4E-BPs). Sumoylation of eIF4E on five lysines is promoted by its
phosphorylation at S209, and results in its dissociation from 4E-
BP1. Sumoylation did not interfere with mRNA recognition but
enhanced eIF4F complex assembly on the mRNA cap, promoting
the expression of ornithine decarboxylase, c-myc and Bcl-2,
driving the anti-apoptotic and oncogenic activity of eIF4E [33]. As
phosphorylation of eIF4E has been shown to play a role in
selective nuclear export of mRNA [71], it is likely that sumoylation
of eIF4E occurs in the nucleus and/or as it emerges into the
cytoplasm
We have shown that in response to osmotic stress (1 M KCl),
conditions that induce stress granules in fission yeast, the overall
levels of SUMO and eIF4G are reduced. We have also shown that
under these conditions, there is increased sumoylation of eIF4G.
The role of this modification is not known. Our results suggest two
possible scenarios: the first being that sumoylation is targeting
eIF4G for degradation, possibly via the action of a SUMO-
targeted ubiquitin ligase (STUbL). The second possibility is that
sumoylation may be targeting eIF4G to stress granules. Further
work is needed to distinguish between these two possibilities.
The two sumoylation sites in human eIF4GI that we have
identified are not conserved in fission yeast eIF4G, as this protein
lacks the C-terminal domains present in human eIF4GI
(Figure 7B). Their positions suggest that sumoylation of this
protein may be affecting interactions of eIF4GI with eIF4A and
Mnk1. eIF4A is a DEAD-box protein that participates in
translation initiation and binds to eIF4GI [18,21,22]. Functioning
as an ATP-dependent RNA helicase, eIF4A is believed to unwind
secondary structure in the 59-untranslated region of mRNAs to
enable ribosome scanning. The RNA-stimulated ATPase and
ATP-dependent helicase activities of eIF4A are enhanced by its
interaction with two domains on eIF4GI, one in the C-terminus
and one in the middle domain [18,22]. Interaction and subsequent
recycling of eIF4A from the eIF4G/eIF4A complex stimulates the
eIF4A helicase activity required for the mRNA scanning process.
It is possible that sumoylation of eIF4GI either directly or
indirectly affects the interaction with eIF4A, thereby regulating
translation initiation. Mnk1 is a kinase which binds at the extreme
C-terminus of eIF4GI and regulates the phosphorylation of eIF4E
at Ser209 [18,21,22]. Phosphorylated eIF4E has been shown to be
modified by sumoylation on five lysine residues [33] promoting
eIF4F complex formation and specific protein synthesis [33].
Sumoylation of K1588 on eIF4GI could prevent the binding of
Mnk1, reduce eIF4E phoshorylation and thereby abrogate
sumoylation of eIF4E and specific mRNA translation. As
phosphorylation of eIF4E is associated with tumour cell formation
and increased resistance of tumour cells to apoptosis, sumoylation
of eIF4GI at this site could provide a novel and undiscovered
mechanism to regulate cell growth and proliferation in mamma-
lian cells. Further work needs to be done to address this.
In conclusion, our results demonstrate that S. pombe and human
eIF4GI are both sumoylated, and that in S. pombe this modification
is increased under conditions that promote the formation of stress
granules. We have also identified the target lysine residues that are
used for sumoylation in vitro in human eIF4GI. It will be of interest
to determine whether these sites are also used in vivo, and to
identify the role of this sumoylation.
Supporting Information
Figure S1 Comparison of proteins co-purifying with
Ulp2-Tap and Rad9-Tap. Extracts from cells expressing Ulp2-
Tap, Rad9-Tap (Methods S1) or Tap alone were subjected to the
same purification procedure and analysed by SDS-PAGE followed
by staining with colloidal coommassie.
(TIF)
Figure S2 Colocalisation of eIF4G with PABP. A. Strain
containing eIF4G-HA and PABP-RFP stained with anti-HA and
anti-RFP antisera. Secondary antisera: anti-rabbit FITC conju-
gated, anti-mouse TRITC-conjugated. B. Strains containing either
eIF4G-HA or Pabp-RFP (Methods S1) as indicated, stained with
anti-SUMO antisera.
(TIF)
Table S1 Identity of proteins co-purifying with Ulp2-
TAP. Proteins identified by LC MS/MS (Methods S1).
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